MedPath

Effect of Ayurvedic medicine in ADHD in children of age 6 to 12 years

Phase 2
Not yet recruiting
Conditions
Attention-deficit hyperactivity disorder, unspecified type. Ayurveda Condition: BALAROGAH,
Registration Number
CTRI/2025/06/089402
Lead Sponsor
Anjali Pratap Thawrani
Brief Summary

This study is a randomized open labelled controlled clinical trial comparing the safety and efficacy of Dheeradi ghrita 4ml thrice a day  with koshna jala and controlled shankhpushpi and jatamansi siddha ghrita 4ml thrice a day with koshna jala for 45 days in 60 children of age group 6 to 12 yrs with Attention Deficit Hyperactivity Disorder (ADHD)

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Age group between 6 to 12 yrs.
  • Patient irrespective of their gender, religion and socioeconomic status.
  • Patients having Symptoms of ADHD for at least last 6 months.
  • Patients that fit in DSM IV criteria for diagnosis.
  • Children with no other neurological condition like mental retardation, down syndrome, microcephaly, etc.
Exclusion Criteria
  • Any serious neurological disease diagnosed earlier like cerebral palsy, mental retardation, microcephaly.
  • Any kind of systemic disease or chronic systemic disease like nephrotic syndrome, type 1 diabetes melitus.
  • disobedient parents.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the effect of Dheeradi Ghrita in ADHD15 days
Secondary Outcome Measures
NameTimeMethod
To understand the disease ADHD in detail.To find out ayurvedic correlation of disease with doshas and dushya.

Trial Locations

Locations (1)

Siddhakala Ayurved Mahavidyalaya, Sangamner

🇮🇳

Ahmadnagar, MAHARASHTRA, India

Siddhakala Ayurved Mahavidyalaya, Sangamner
🇮🇳Ahmadnagar, MAHARASHTRA, India
Dr Anjali Pratap Thawrani
Principal investigator
09404563407
anjalithawrani1998@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.